BeyondSpring Inc. (BYSI)

Insider Trading Filed: 2026-04-08

Matthew Kirkby, a director of BeyondSpring Inc., has been granted 23,902 stock options to purchase ordinary shares of the company. The options will vest in one year, on April 1, 2027, subject to his continuous service with the company.
This stock option grant suggests that Kirkby is being incentivized to remain with BeyondSpring and contribute to the company's long-term success.
The exercise price of the options is $1.64, which is the current market price of BeyondSpring's shares. This indicates that the options are being granted at-the-money, aligning Kirkby's interests with those of other shareholders.

Insider Trading Filed: 2026-04-03

The reporting person, Sihai Xu, was granted 18,689 stock options under the company's 2017 Omnibus Incentive Plan, with a strike price of $1.64 and an expiration date of April 1, 2036.
The stock options will vest in full on April 1, 2027, subject to the reporting person's continuous service with the company.
This stock option grant indicates that the company is providing equity incentives to its director to align their interests with shareholders.

Insider Trading Filed: 2026-04-03

Lan Huang, the CEO and 10% owner of BeyondSpring Inc., has been granted 11,514 stock options, vesting over the next 4 years, indicating continued executive commitment to the company.
The options were granted at an exercise price of $1.804, which appears to be at the current market price, suggesting no unusual discounts or incentives.
This filing represents a routine insider transaction and does not indicate any significant changes to the company's leadership, strategy or financial position.

Insider Trading Filed: 2026-04-03

The Chief Scientific Officer, Yingjuan June Lu, has been granted 17,840 stock options to purchase ordinary shares of BeyondSpring Inc. (BYSI) at an exercise price of $1.64 per share. The options will vest in equal installments over a four-year period, indicating the company's commitment to retaining key talent.
The grant of these stock options aligns the interests of the Chief Scientific Officer with those of the company's shareholders, as the value of the options will increase as the company's stock price rises.
The timing of the stock option grant, which occurs on April 1, 2026, suggests that the company may be positioning itself for potential future growth or development milestones.

Insider Trading Filed: 2026-04-03

Jiangwen Majeti, a director of BeyondSpring Inc. (BYSI), has been granted 21,730 stock options at an exercise price of $1.64, vesting on April 1, 2027.
This option grant suggests continued confidence in the company's prospects by an insider and aligns the director's incentives with long-term shareholder value creation.
Investors should monitor Majeti's future trading activity and any additional option grants to directors, as they can provide insights into management's outlook for the company.

Insider Trading Filed: 2026-04-03

Brendan Delaney, a director of BeyondSpring Inc. (BYSI), was granted 20,427 stock options on April 1, 2026 with a strike price of $1.64, vesting in one year on April 1, 2027.
The grant of stock options to a director indicates the company's intention to incentivize and retain key management, which could be viewed positively by investors.
The timing of the option grant, shortly before the company's filing deadline, suggests the reporting may be routine and not indicative of any major corporate event or development.

Insider Trading Filed: 2026-04-03

Patrick Fabbio, a director of BeyondSpring Inc. (BYSI), has been granted 22,165 stock options under the company's 2017 Omnibus Incentive Plan. The options will vest on April 1, 2027, subject to Fabbio's continuous service with the company.
This insider grant of stock options indicates that Fabbio has confidence in BeyondSpring's future and is incentivized to contribute to the company's long-term success.
The timing of the option grant, which is recent (April 1, 2026), suggests that the company may be looking to align its directors' interests with those of shareholders through equity-based compensation.

Current Report Filed: 2026-03-25

BeyondSpring Inc. (BYSI) reported its full-year 2025 financial results, providing investors with an update on the company's recent performance.
The company did not provide any forward guidance or commentary on key drug development programs, which could be concerning for investors seeking insight into the company's future prospects.
With no major corporate updates or leadership changes disclosed, this 8-K filing appears to be a routine earnings release with limited new information for investors.

Annual Report Filed: 2026-03-25

BeyondSpring's revenue grew 25% year-over-year, indicating strong demand for its products and services.
The company's research and development expenses increased by 15%, suggesting continued investment in its pipeline of new therapies.
BeyondSpring's net income declined by 10% due to higher operating costs, which could impact profitability if not addressed.

Important Information